Home  /  Resource Library  /  CD19-CAR T Cells Treatment for Minimal Residual Disease in B-Cell Lymphoma with a Higher Response Rate and Fewer Adverse Reactions

CD19-CAR T Cells Treatment for Minimal Residual Disease in B-Cell Lymphoma with a Higher Response Rate and Fewer Adverse Reactions

Results of a study investigating CD19 CAR T-cell therapy for treating relapsed diffuse large b-cell lymphoma.